The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 730-741

  Devy, Jérôme ^a   Ouchani, Farid ^a   Oudot, Christelle ^a   Helesbeux, Jean Jacques ^b   Vanquelef, Enguerran ^b   Salesse, Stéphanie ^a   Rabenoelina, Fanja ^a   Al Khara, Siana ^a   Letinois, Isabelle ^a   Duval, Olivier ^b   Martiny, Laurent ^a   Charpentier, Emmanuelle ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Acute lymphoblastic leukemia; Ethoxyfagaronine; Matrigel invasion; MT1 MMP; Plasmin activity

Indexed keywords

ANTILEUKEMIC AGENT; ETHOXYFAGARONINE; MATRIX METALLOPROTEINASE; MELATONIN 1 RECEPTOR; PLASMIN; PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; ALKALOID; APROTININ; BENZOPHENANTHRIDINE DERIVATIVE; DIPEPTIDE; FAGARONINE; GELATINASE; GELATINASE A; GELATINASE B; ILOMASTAT; MATRIX METALLOPROTEINASE 14; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE; N METHYL 12 ETHOXY 2 HYDROXY 3,8,9 TRIMETHOXYBENZO(C)PHENANTHRIDINIUM; N-METHYL-12-ETHOXY-2-HYDROXY-3,8,9-TRIMETHOXYBENZO(C)PHENANTHRIDINIUM;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; GROWTH INHIBITION; IMMUNOFLUORESCENCE TEST; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; CANCER INVASION; CELL DEATH; CELL PROLIFERATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA L 1210; METABOLISM; PATHOLOGY;

ALKALOIDS; ANIMALS; APROTININ; BENZOPHENANTHRIDINES; CELL DEATH; CELL PROLIFERATION; DIPEPTIDES; DOWN-REGULATION; ENZYME ACTIVATION; FIBRINOLYSIN; GELATINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; LEUKEMIA L1210; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATORS;

EID: 84856067619     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9410-x     Document Type: Article

References (41)

1. Pui CH, Jeha S (2007) New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 6:149-165
2. Ries C, Loher F, Zang C, Ismair MG, Petrides PE (1999) Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 5:1115-1124
3. Lynch CC, McDonnell S (2000) The role of matrilysin (MMP-7) in leukaemia cell invasion. Clin Exp Metastasis 18:401-406
4. Devy L, Hollender P, Munaut C, Colige A, Garnotel R, Foidart JM, Noel A, Jeannesson P (2002) Matrix and serine protease expression during leukemic cell differentiation induced by aclacinomycin and all-trans-retinoic acid. Biochem Pharmacol 63:179-189
5. Stefanidakis M, Koivunen E (2006) Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 108:1441-1450
6. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J (1999) Mechanisms for pro matrix metalloproteinase activation. APMIS 107:38-44
7. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO and Bruserud O (2009) Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol
8. Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C (2008) Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 7:1047-1053
9. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Ishii E, Hara T (2007) Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res 31:1437-1440
10. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR (1999) Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107:120-127
11. Rosmann S, Hahn D, Lottaz D, Kruse MN, Stocker W, Sterchi EE (2002) Activation of human meprin-alpha in a cell culture model of colorectal cancer is triggered by the plasminogen-activating system. J Biol Chem 277:40650-40658
12. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL (1995) The cell biology of the plasminogen system. FASEB J 9:939-945
13. Bene MC, Castoldi G, Knapp W, Rigolin GM, Escribano L, Lemez P, Ludwig WD, Matutes E, Orfao A, Lanza F, Van't Veer M (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia 18:394-400
14. Narla RK, Dong Y, Klis D, Uckun FM (2001) Bis (4, 7-dimethyl-1, 10-phenanthroline) sulfatooxovanadium (I. V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity. Clin Cancer Res 7:1094-1101
15. Philchenkov A, Kaminskyy V, Zavelevich M, Stoika R (2008) Apoptogenic activity of two benzophenanthridine alkaloids from Chelidonium majus L. does not correlate with their DNA damaging effects. Toxicol In Vitro 22:287-295
16. Nakanishi T, Suzuki M, Saimoto A, Kabasawa T (1999) Structural considerations of NK109, an antitumor benzo[c]phenanthridine alkaloid. J Nat Prod 62:864-867
17. Messmer WM, Tin-Wa M, Fong HH, Bevelle C, Farnsworth NR, Abraham DJ, Trojanek J (1972) Fagaronine, a new tumor inhibitor isolated from Fagara zanthoxyloides Lam. (Rutaceae). J Pharm Sci 61:1858-1859
18. Comoe L, Jeannesson P, Trentesaux C, Desoize B, Jardillier JC (1987) The antileukemic alkaloid fagaronine and the human K 562 leukemic cells: effects on growth and induction of erythroid differentiation. Leuk Res 11:445-451
19. Stermitz FR, Larson KA, Kim DK (1973) Some structural relationships among cytotoxic and antitumor benzophenanthridine alkaloid derivatives. J Med Chem 16:939-940
20. Lynch MA, Duval O, Sukhanova A, Devy J, MacKay SP, Waigh RD, Nabiev I (2001) Synthesis, biological activity and comparative analysis of DNA binding affinities and human DNA topoisomerase I inhibitory activities of novel 12-alkoxybenzo[c]phenanthridinium salts. Bioorg Med Chem Lett 11:2643-2646
21. Deroussent A, Re M, Hoellinger H, Vanquelef E, Duval O, Sonnier M, Cresteil T (2004) In vitro metabolism of ethoxidine by human CYP1A1 and rat microsomes: identification of metabolites by high-performance liquid chromatography combined with electrospray tandem mass spectrometry and accurate mass measurements by time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 18:474-482
22. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
23. Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G (1978) Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 7:138-145
24. Agren MS, Mirastschijski U, Karlsmark T, Saarialho-Kere UK (2001) Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol 10:337-348
25. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES (2004) The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50:87-100
26. Polette M, Birembaut P (1998) Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol 30:1195-1202
27. Itoh Y (2006) MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 58:589-596
28. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40
29. Sun X, Li Y, Yu W, Wang B, Tao Y, Dai Z (2008) MT1-MMP as a downstream target of BCR-ABL/ABL interactor 1 signaling: polarized distribution and involvement in BCR-ABL-stimulated leukemic cell migration. Leukemia 22:1053-1056
30. Maruyama T, Yamamoto S, Nojima M, Morita N, Tanizawa T, Shima H (2007) Extramedullary relapse of acute lymphoblastic leukemia in childhood to the prostate. Int J Urol 14:447-449
31. Larsen AK, Grondard L, Couprie J, Desoize B, Comoe L, Jardillier JC, Riou JF (1993) The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 46:1403-1412
32. Vanquelef E, Helesbeux JJ, Duval O, Debiton E, Barthomeuf C, Jarry C, Forfar I, Richomme P (2007) Synthesis and PC3 androgen-independent prostate cells antiproliferative effect of fagaronine derivatives. J Enzyme Inhib Med Chem 22:647-654
33. Geran RI, Greenberg NH, Macdonald MM and Abbott BJ (1977) Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI. Natl Cancer Inst Monogr 151-3
34. Li S, Chen ZX, Wang W, Cen JN, Fu JX, Yao L (2003) The expression and clinical implication of gelatinase A in acute leukemic cells. Zhonghua Nei Ke Za Zhi 42:684-687
35. Szabova L, Chrysovergis K, Yamada SS, Holmbeck K (2008) MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 27:3274-3281
36. Yu W, Sun X, Clough N, Cobos E, Tao Y, Dai Z (2008) Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Carcinogenesis 29:1717-1724
37. Gu BJ, Wiley JS (2006) Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 107:4946-4953
38. Wei W, Ryu JK, Choi HB, McLarnon JG (2008) Expression and function of the P2X[7] receptor in rat C6 glioma cells. Cancer Lett 260:79-87
39. Shemon AN, Sluyter R, Conigrave AD, Wiley JS (2004) Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. Br J Pharmacol 142:1015-1019
40. Lanza F, Castoldi GL, Castagnari B, Todd RF 3rd, Moretti S, Spisani S, Latorraca A, Focarile E, Roberti MG, Traniello S (1998) Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol 103:110-123
41. Mustjoki S, Alitalo R, Stephens RW, Vaheri A (1999) Plasminogen activation in human leukemia and in normal hematopoietic cells. APMIS 107:144-149